Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer
| Autor: | Hiroko Yamashita, Norikazu Masuda, Mitsuchika Hosoda, Hiroyoshi Doihara, Nobumoto Tomioka, Naoko Ishida, Yuichiro Miyoshi, Tomofumi Osako, Masato Takahashi, Hiroyuki Yasojima, Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Touko Inao, Yoshiya Horimoto, Yumi Wanifuchi‑Endo |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Estrogen receptor 03 medical and health sciences 0302 clinical medicine Breast cancer breast cancer Internal medicine Progesterone receptor medicine Clinical significance estrogen receptor positive Chemotherapy business.industry Tumor-infiltrating lymphocytes Cancer Retrospective cohort study Articles medicine.disease 030104 developmental biology tumor infiltrating lymphocytes 030220 oncology & carcinogenesis prognosis business human epidermal growth factor receptor type 2 negative |
| Zdroj: | Oncology Letters |
| ISSN: | 1792-1074 |
| Popis: | The value of assessing tumor infiltrating lymphocytes (TILs) in estrogen receptor (ER) positive/human epidermal growth factor receptor type 2 (HER2) negative breast cancer has yet to be determined. In the present study, a total of 184 cases with early distant recurrence detected within 5 years following the primary operation, 134 with late distant recurrence diagnosed following 5 years or longer and 321 controls without recurrence for >10 years following starting the initial treatment for ER-positive/HER2 negative breast cancer, registered in 9 institutions, were analyzed. The distributions of TILs and their clinical relevance were investigated. TIL distributions did not differ significantly among the early, late and no recurrence groups, employing a 30% cut-off point as a dichotomous variable. In those who had received adjuvant chemotherapy as well as endocrine therapy, a trend toward higher TIL proportions was detected when the early recurrence group was compared with the no recurrence group employing the 30% cut-off point (P=0.064). The TIL distributions were significantly associated with nodal metastasis (P=0.004), ER status (P=0.045), progesterone receptor (PgR) status (P=0.002), tumor grade (P=0.021), and the Ki67 labeling index (LI) (P=0.002) in the no recurrence group and with the Ki67 LI in the recurrence groups (P=0.002 in early recurrence group, P=0.023 in late recurrence group). High TIL distributions also predicted shorter survival time following the detection of recurrence (P=0.026). However, these prognostic interactions were not significant in multivariate analysis (P=0.200). The present retrospective study demonstrated no significant interaction between TIL proportions and the timing of recurrence. However, higher TIL proportions were observed in breast cancer patients with aggressive biological phenotypes, which tended to be more responsive to chemotherapy. The clinical relevance of stromal TILs for identifying patients who would likely benefit from additional therapies merits further investigation in a larger patient population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|